Molecular Mechanisms of Chemotherapy-Induced Cognitive Dysfunction
Molecular Mechanisms of Chemotherapy-Induced Cognitive Dysfunction
批准号:
10305701
负责人:
Khalid S Mohammad
金额:
$15.45万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-09 至 2022-08-31
关键词:
BehaviorBrainCalciumChemicalsChemotherapy-Oncologic ProcedureDataDoxorubicinEndoplasmic ReticulumExhibitsFluorouracilFunctional disorderGoalsHeart DiseasesHumanImpaired cognitionLegal patentLinkMemory impairmentMethotrexateModelingMolecularMusMyopathyNeurocognitiveNeuronsOralOxidesPathologyPharmaceutical PreparationsPost-Translational Protein ProcessingPost-Traumatic Stress DisordersProductivityPublishingResearchResearch PersonnelRyR2Ryanodine Receptor Calcium Release ChannelSafetySalesSignal TransductionSpecialistStressSupervisionTestingTraining SupportUniversitieschemobrainchemotherapeutic agentchemotherapyclinically relevantcognitive functionexperimental studyimprovedin vivomalignant breast neoplasmmembermouse modelnovelnovel therapeuticspreventresearch clinical testingsmall moleculesuccesstreatment strategy
中文摘要
项目摘要/摘要
认知功能障碍(化疗)是癌症化疗的重要不良后遗症,
NCI认为这是一个知之甚少的问题,目前的管理层或
治疗策略有限或无效。我们的初步数据显示神经元兰尼定
内质网(ER)上的受体/钙释放通道(RyR2)被氧化并“泄漏”
阿霉素或甲氨蝶呤联合5-FU治疗小鼠。这些小鼠表现出认知功能障碍,可以
使用由co-PI开发的新型口服可用小分子药物(Rycal,S107)进行改进
泄漏的RyR2频道。本应用程序的目标是:(1)建立和鉴定一种小鼠模型。
晚期人类乳腺癌可用于研究细胞内钙离子是否通过
内质网上氧化的神经元RyR2是化疗诱导肿瘤的一种新机制
神经认知功能障碍;以及(2)测试修复泄漏神经元RyR2的新药Rycal(S107)
体内的通道可以防止化学阻塞。拟议的研究将具有重要的临床意义,因为
Rycal S107与目前正在进行临床测试的两种密切相关的Rycal属于同一化学类别
心脏和肌肉疾病,到目前为止,这两种药物都有很好的安全性。S107的优势在于它是
浓缩>;10倍于大脑。(虽然S107是哥伦比亚大学的专利,美国8,710,045,
14年4月29日,该药物向所有调查人员提供,申请人没有从其销售中获得任何收益)。这
初步数据显示,常用的化疗药物会导致认知
使用Rycal S107可以预防C57BL6小鼠的功能障碍,我们公布的数据显示
神经元RyR2通道的泄漏会导致应激诱导的认知功能障碍(创伤后应激
精神障碍、创伤后应激障碍),可通过口服S107改善。此应用程序旨在使
化学负荷和创伤后应激障碍之间的新机制联系--细胞内钙离子泄漏--并测试一种潜在的
防止这种渗漏和防止化学污染的新疗法。研究专家穆罕默德博士将
建立有和没有乳腺癌的小鼠模型,并建立认知功能障碍的存在
通过测试几种化疗药物来建立这些模型。穆罕默德博士将执行必要的
与其他团队成员一起进行实验,提供监督和培训支持,以保持高水平的
项目成功所需的研究一致性和生产力。
英文摘要
Project Summary/Abstract
Cognitive dysfunction (“chemobrain”) is an important adverse sequel of cancer chemotherapy, the study of
which has been identified by the NCI as a poorly understood problem for which current management or
treatment strategies are limited or ineffective. Our preliminary data show that neuronal ryanodine
receptor/calcium release channels (RyR2) on the endoplasmic reticulum (ER) become oxidized and “leaky” in
mice treated with doxorubicin or methotrexate plus 5-FU. These mice exhibit cognitive dysfunction that can be
improved using a novel orally available small molecule drug (Rycal, S107) developed by the co-PI that fixes
leaky RyR2 channels. The goals of this application are to: (1) establish and characterize a murine model of
advanced human breast cancer that can be used to study whether intracellular calcium (Ca2+) leak via
oxidized neuronal RyR2 on the ER is a novel mechanism underlying cancer chemotherapy-induced
neurocognitive dysfunction; and (2) test whether the novel drug Rycal (S107) that fixes leaky neuronal RyR2
channels in vivo can prevent chemobrain. The proposed studies will have important clinical relevance as the
Rycal S107 is in the same chemical class as two closely related Rycals that are currently in clinical testing for
heart and muscle disorders, and to date both have excellent safety profiles. S107 has the advantage that it is
concentrated >10-fold in the brain. (Although S107 is patented by Columbia University, US 8,710,045,
04/29/14, the drug is available to all investigators and the applicant receives no proceeds from its sale). This
application is bolstered by preliminary data showing that commonly used chemotherapeutics cause cognitive
dysfunction in C57BL6 mice that can be prevented using the Rycal S107, and by our published data showing
that leaky neuronal RyR2 channels can cause stress-induced cognitive dysfunction (post-traumatic stress
disorder, PTSD) that can be ameliorated by oral treatment with S107. This application aims to make the
novel mechanistic link between chemobrain and PTSD - intracellular Ca2+ leak - and to test a potential
novel therapy that prevents this leak and prevents chemobrain. Research specialist, Dr. Mohammad, will
set up mouse models, with and without breast cancer, and establish the presence of cognitive dysfunction in
those models by testing several chemotherapeutic agents. Dr. Mohammad will perform the necessary
experiments with other team members, providing supervision and training support to maintain the high level of
research consistency and productivity required for project success.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Mechanisms of Chemotherapy-Induced Cognitive Dysfunction
-
批准号:10267427
-
项目类别:
-
资助金额:$15.12万
-
财政年份:2019
-
负责人:Khalid S Mohammad
-
依托单位:
国内基金
海外基金
Sitagliptin通过microbiota-gut-brain轴在2型糖尿病致阿尔茨海默样变中的脑保护作用机制
-
批准号:81801389
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:田茗源
-
依托单位:
平扫描数据导引的超低剂量Brain-PCT成像新方法研究
-
批准号:81101046
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:黄静
-
依托单位: